Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia
NCT05741853
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Difficulties with speech and language are the first and most notable symptoms of primary progressive aphasia (PPA). While there is evidence that demonstrates positive effects of speech-language treatment for individuals with PPA who only speak one language (monolinguals), there is a significant need for investigating the effects of treatment that is optimized for bilingual speakers with PPA. This stage 2 efficacy clinical trial seeks to establish the effects of culturally and linguistically tailored speech-language interventions administered to bilingual individuals with PPA.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Primary Progressive Aphasia
- Dementia
- Dementia, Frontotemporal
- Alzheimer Disease
- Neurodegenerative Diseases
- Frontotemporal Lobar Degeneration
- Apraxia, Motor
- Dysarthria
- Communication Disorders
- Language Disorders
- Speech Disorders
- Neurocognitive Disorders
- Aphasia
- Bilingual Aphasia
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Stephanie Grasso
- Last updated on ClinicalTrials.gov
- June 10, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Texas · 1
- University of Texas at Austin · Austin, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.